Isodiol: An Execution Story
Over the last year, Isodiol International Inc. (ISOL:CNX) (ISOLF) has been executing flawlessly and has been laser focused on securing strategic partners and making accretive acquisitions.
The global Bioactive Phytoceutical innovator has been able to significantly advance its fundamental story by partnering with leading cannabis companies like Canopy Growth (WEED:APH) (TWMJF), Nuuvera (NUU:APH) and Namaste Technologies (N:CNX) (NXTTF). We are excited by these partnerships and believe that they will help support growth in 2018 and beyond.
Last month, Isodiol released third quarter financial results and recorded almost $6 million in revenue which is incrementally higher than the same period last year. Isodiol attributed the growth and profit increase to increased distribution, portfolio diversification, and the continued integration of wholly owned subsidiaries.
We are favorable on this growth and will monitor how these numbers continue to improve as Isodiol executes on organic and inorganic growth initiatives. We are favorable on this multi-faceted growth strategy and will monitor the impact it has on revenue numbers over the coming quarters.
Isodiol continues to execute on previously announced initiatives and is led by a management team with a proven track record. We are excited by the continued execution and believe the company is well positioned to report strong growth on a quarter-over-quarter basis going forward.
Although Isodiol continues to advance and improve the fundamental story, the shares have been under pressure and we are monitoring this decline. Momentum is approaching oversold levels after the shares fell more than 10% in the last week and investors need to keep an eye on this global leader.
Authored by Michael Berger Michael Berger is the Founder of Technical420 and Managing Partner of StoneBridge Partners. Michael continues to be one of the top authorities on cannabis equities in the industry.